DOJ, US Cham­ber lay out de­bate over drug price ne­go­ti­a­tion lit­i­ga­tion in Ohio court

Lawyers from the De­part­ment of Jus­tice and US Cham­ber of Com­merce bat­tled be­fore an Ohio dis­trict court judge over whether the Cham­ber’s law­suit over the new drug price ne­go­ti­a­tions should be dis­missed, and whether CMS’ ne­go­ti­a­tion of drug prices is re­al­ly a ne­go­ti­a­tion.

On the DOJ’s side, se­nior tri­al coun­sel Stephen Pezzi told the court Fri­day that the US Cham­ber’s case should be dis­missed on stand­ing, par­tic­u­lar­ly as it’s Ab­b­Vie’s sub­sidiary Phar­ma­cyclics that is the pri­ma­ry man­u­fac­tur­er of Im­bru­vi­ca — one of 10 drugs re­cent­ly se­lect­ed for ne­go­ti­a­tions — and Phar­ma­cyclics should be the one un­der which the Cham­ber’s suit should’ve been filed, not Ab­b­Vie.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER